FOS and neoplasm: Alterations in FOS expression have been associated with malignant phenotypic changes in tumor cells [30], while downregulation of CCL2 and CAV1 may influence immune cell recruitment and signaling within the tumor microenvironment, thereby affecting tumor immune evasion and progression [31,32].